<div id="readability-page-1"><div><p>Looking at <strong>CARsgen Therapeutics Holdings Limited's</strong> (HKG:2171 ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders than there were sold.</p><p> Although we don't think shareholders should simply follow insider transactions,  we would consider it foolish to ignore insider transactions altogether. </p> <p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p><h2> CARsgen Therapeutics Holdings Insider Transactions Over The Last Year </h2> <p> In fact, the recent purchase by Non-Executive Director Huaqing Guo was not their only acquisition of CARsgen Therapeutics Holdings shares this year.  Earlier in the year, they paid HK$14.80 per share in a HK$1.0m purchase.     That implies that an insider found the current price of HK$14.88 per share to be enticing.  That means they have been optimistic about the company in the past, though they may have changed their mind.  While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed.   In this case we're pleased to report that the insider bought shares at close to current prices.  The only individual insider to buy over the last year was Huaqing Guo.    </p> <p> Huaqing Guo bought a total of 276.50k shares over the year at an average price of HK$16.44.   You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below.  By clicking on the graph below, you can see the precise details of each insider transaction! </p><p><span> View our latest analysis for CARsgen Therapeutics Holdings </span></p><figure><img height="872" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/713821465-insider-trading-volume-1-dark-2/1765927037722?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1642" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/713821465-insider-trading-volume-1-dark-2/1765927037722"/><figcaption>SEHK:2171 Insider Trading Volume December 16th 2025</figcaption></figure><p> CARsgen Therapeutics Holdings is not the only stock that insiders are buying. For those who like to find <strong>small cap companies at attractive valuations, </strong> this <strong>free</strong> list of growing companies with recent insider purchasing, could be just the ticket. </p><h2> Does CARsgen Therapeutics Holdings Boast High Insider Ownership? </h2><p> For a common shareholder, it is worth checking how many shares are held by company insiders.  I reckon it's a good sign if insiders own a significant number of shares in the company.   CARsgen Therapeutics Holdings insiders own about HK$161m worth of shares. That equates to 1.9% of the company.  This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.  </p><h2> So What Do The CARsgen Therapeutics Holdings Insider Transactions Indicate? </h2><p> It's certainly positive to see the recent insider purchase.    We also take confidence from the longer term picture of insider transactions.   However, we note that the company didn't make a profit over the last twelve months, which makes us cautious.     Once you factor in the high insider ownership, it certainly seems like insiders are positive about CARsgen Therapeutics Holdings.  That's what I like to see!      Therefore, you should definitely take a look at this <strong>FREE</strong> report showing analyst forecasts for CARsgen Therapeutics Holdings. </p><p> But note: <strong>CARsgen Therapeutics Holdings may not be the best stock to buy</strong>. So take a peek at this <strong>free</strong> list of interesting companies with high ROE and low debt. </p><p><em>For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.</em></p><div><p>Mobile Infrastructure for Defense and Disaster</p><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p><p>Get the investor briefing before the next round of contracts</p><p><span>Sponsored On Behalf of CiTech</span></p></div></div></div>

02171

<p>Insiders at CARsgen Therapeutics Holdings Limited (HKG:2171) were net buyers over the last year, with Non-Executive Director Huaqing Guo purchasing 276.50k shares at an average price of HK$16.44. Insiders own about HK$161m worth of shares, equating to 1.9% of the company. This insider activity suggests optimism about the company's future, despite it not making a profit in the last twelve months.</p>

CARsgen Therapeutics Holdings Insider Ups Holding During Year